Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups
Domaines
Sciences du Vivant [q-bio]
Fichier principal
Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10.pdf (380.36 Ko)
Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Loading...